Outlook Therapeutics, a biopharmaceutical company, has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the NORSE EIGHT clinical trial protocol. This trial will evaluate ONS-5010, the first ophthalmic formulation of bevacizumab, in neovascular age-related macular degeneration (AMD) subjects. Additionally, the company has secured a private placement of up to $172 million in gross proceeds to fund the advancement of ONS-5010.
ONS-5010 has shown promise in the treatment of retinal diseases and Outlook Therapeutics aims to achieve FDA approval for this novel ophthalmic formulation. The FDA’s agreement under the SPA for the NORSE EIGHT trial protocol is a significant milestone in the regulatory process for ONS-5010.
The NORSE EIGHT trial will focus on evaluating the efficacy and safety of ONS-5010 in neovascular AMD subjects. Neovascular AMD is a leading cause of vision loss in older adults, and there is a pressing need for effective treatment options. ONS-5010 has the potential to address this unmet medical need and provide a viable treatment option for patients suffering from neovascular AMD.
In addition to the FDA agreement, Outlook Therapeutics has entered into securities purchase agreements with certain institutional and accredited investors. This private placement aims to raise up to $172 million in gross proceeds to support the development and advancement of ONS-5010. The funds raised from this placement will enable the company to conduct further clinical trials, obtain necessary regulatory approvals, and bring ONS-5010 closer to commercialization.
The successful completion of the NORSE EIGHT trial and subsequent FDA approval would be a significant achievement for Outlook Therapeutics. It would not only expand treatment options for neovascular AMD patients but also potentially pave the way for innovative ophthalmic formulations in the field of retinal diseases.
Comments